Zoetis Reports Solid Q4 & Full-Year 2025 Results, Provides Positive 2026 Guidance

summarizeSummary

Zoetis Inc. announced strong fourth quarter and full-year 2025 financial results, with revenue and net income growth, and issued positive guidance for full-year 2026, driven by product innovation and strategic acquisitions.

check_boxKey Events

• Q4 2025 Financial Performance

  Reported revenue of $2.4 billion, an increase of 3% (4% organic operational), and net income of $603 million, up 4%.

• Full-Year 2025 Results

  Achieved $9.5 billion in revenue, growing 2% (6% organic operational), and net income of $2.7 billion, an 8% increase.

• Positive 2026 Guidance

  Provided full-year 2026 revenue guidance of $9.825-$10.025 billion (3% to 5% organic operational growth) and adjusted diluted EPS of $7.00-$7.10.

• Product Innovation Milestones

  Received regulatory approvals in Canada and the EU for Lenivia (dogs) and Portela (cats), new long-acting monoclonal antibodies for osteoarthritis pain.

auto_awesomeAnalysis

Zoetis delivered a robust performance in 2025, marked by consistent revenue and earnings growth across both reported and organic operational metrics. The company's strategic focus on innovation is evident with key regulatory approvals for long-acting osteoarthritis pain products and the acquisition of Veterinary Pathology Group, enhancing its diagnostics capabilities. While the U.S. segment saw a slight decline in companion animal products due to specific monoclonal antibodies, this was largely offset by growth in other areas and strong international performance. The positive 2026 guidance, projecting continued organic operational growth, reinforces management's confidence in its diversified portfolio and pipeline, which includes 12 potential blockbuster candidates. Investors should monitor the launch success of new OA pain products and the integration of the recent acquisition.